GlassScriptPhysician profile
Bahareh Hassanzadeh
NPI 1528350303
$2,588.60
in general payments reported to CMS, 2019-2025
25 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.78 · 2022: $314 · 2023: $597 · 2024: $853 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.39 | 2022-2025 | |
| Amgen INC. | $216.46 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $197.49 | 2021-2023 | Tepezza, Uplizna |
| Celgene Corporation | $182.35 | 2022-2025 | Zeposia |
| Biogen, INC. | $136.76 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Emd Serono, INC. | $127.71 | 2022-2023 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $98.48 | 2024 | Zeposia |
| Genentech USA, INC. | $91.43 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $79.28 | 2023-2024 | Emgality, Amyvid |
| Alexion Pharmaceuticals, INC. | $78.44 | 2023-2024 | Ultomiris, Soliris |
| Eisai INC. | $69.92 | 2023-2024 | |
| Lundbeck LLC | $65.72 | 2024-2025 | Vyepti |
| Ucb, INC. | $56.52 | 2023-2025 | Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $54.38 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $52.78 | 2025 | Nuplazid, Daybue |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.00 | 2025 | |
| Argenx US, INC. | $45.90 | 2023-2024 | Vyvgart Hytrulo |
| Pfizer INC. | $44.50 | 2024 | |
| Vanda Pharmaceuticals INC. | $34.28 | 2025 | Ponvory |
| Mallinckrodt Hospital Products INC. | $34.12 | 2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2025 | Hyqvia |
| Csl Behring | $24.99 | 2025 | Hizentra |
| Tg Therapeutics, INC. | $24.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.21 | 2021 | |
| Cycle Pharmaceuticals INC | $13.84 | 2025 | Bafiertam, Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahareh Hassanzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.